With the neoadjuvant regimen of pembrolizumab added to dabrafenib and trametinib, survival in BRAF-mutated forms of the highly aggressive cancer can go from months to more than 5 years.
Expert oncologists work together to review the treatment armamentarium for radioiodine-refractory differentiated thyroid cancer and identify factors that best inform selection of therapy.
For patients with metastatic melanoma, triplet therapy with atezolizumab and vemurafenib plus cobimetinib provides significant survival benefits, but the regimen may not be cost-effective, researchers say.